Nonestrogenic drugs and breast cancer

American Journal of Epidemiology

Volumn 116, Issue 2, 1982, Pages 329-332

  Danielson, David A ^a   Jick, Hershel ^a   Hunter, Judith R ^b   Stergachis, Andy ^b   Madsen, Sue ^b  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^b CENTER FOR HEALTH STUDIES   (United States)

Author keywords

Breast neoplasms; Drugs; Risk

Indexed keywords

DIAZEPAM; DIGITALIS; MEDROXYPROGESTERONE ACETATE; METHYLDOPA; METRONIDAZOLE; PHENOTHIAZINE; PHENOTHIAZINE DERIVATIVE; RESERPINE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; THYROID HORMONE; THYROXINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADVERSE DRUG REACTION; BREAST; BREAST CANCER; BREAST CARCINOMA; CANCER RISK; CARCINOGENESIS; DRUG COMPARISON; EPIDEMIOLOGY; ETIOLOGY;

ADULT; AGED; BREAST NEOPLASMS; DRUG THERAPY; FEMALE; FOLLOW-UP STUDIES; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; MIDDLE AGED; RISK; WASHINGTON;

EID: 0019960587     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.aje.a113416     Document Type: Article

References (23)

1. Lawson DH, Jick H, Hunter JR, et al. Exogenous estrogens and breast cancer. Am J Epidemiol 1981; 114: 710-13.
2. Jick H, Walker AM, Watkins RN, et al. Replacement estrogens and breast cancer. Am J Epidemiol 1980; 112: 586-94.
3. Jick H, Walker AM, Watkins RN, et al. Oral contraceptives and breast cancer. Am J Epidemiol 1980; 112: 577-85.
4. Horrobin DF, Ghayur T, Karmali RA. Mind and cancer (letter). Lancet 1979; 1: 978.
5. Stenkvist B, Bengtsson E, Eriksson O, et al. Cardiac glycosides and breast cancer (letter). Lancet 1979; 1: 563.
6. MacMahon B, Cole P, Brown J. Etiology of human breast cancer: a review. JNCI 1973; 50: 21-42.
7. Williams RR. Breast and thyroid cancer and malignant melanoma promoted by alcohol- induced pituitary secretion of prolactin, T. S. H., and M. S. H. Lancet 1976; 1: 996-9.
8. Mack TM, Henderson BE, Gerkins VR, et al. Reserpine and breast cancer in a retirement community. N Engl J Med 1975; 292: 1366-71.
9. Ettigi P, Lai S, Friesen HG. Prolactin, phenothiazines, admission to mental hospital, and carcinoma of the breast (letter). Lancet 1973; 2: 266-7.
10. Loube SD, Quirk RA. Breast cancer associated with administration of spironolactone (letter). Lancet 1975; 1: 1428-9.
11. Goldman P, Ingelfinger JA, Friedman PA. Metronidazole, isoniazid and the threat of human cancer. In: Hiatt HH, Watson JD, Winsten JA, eds. Origins of human cancer. Book A, Incidence of cancer in humans. New York: Cold Spring Harbor Laboratory, 1977: 465-74.
12. Kapdi CC, Wolfe JN. Breast cancer: relationship to thyroid supplements for hypothyroidism. JAMA 1976; 236: 1124-27.
13. Rothman KJ, Boice JD Jr. Epidemiologic analysis with a programmable calculator. Washington DC, US GPO, 1979. (DHEW Publication No. (NIH) 79-1649).
14. Pearson OH. Endocrine aspects of breast cancer. In: Anfinsen CB, et al, eds. Current Research in Oncology. New York: Academic Press, 1972: 125.
15. Shapiro S, Slone D, Kaufman DW, et al. Use of thyroid supplements in relation to the risk of breast cancer. JAMA 1980; 244: 1685-7.
16. Kleinerman RA, Rinton LA, Hoover R, et al. Diazepam and breast cancer (letter). Lancet 1981; 1: 1153.
17. Brugmans J, Verbruggen F, Dom J, et al. Prolactin, phenothiazines, admission to mental hospital, and carcinoma of the breast (letter). Lancet 1973; 2: 502-3.
18. Friedman FD, Ury HK. Initial screening for carcinogenicity of commonly used drugs. JNCI 1980; 65: 723-33.
19. Jick H, Armstrong B. Breast cancer and spironolactone (letter). Lancet 1975; 2: 368-9.
20. Bridgman JF, Buckler JMH. Drug-induced gynaecomastia Getter). Br Med J 1974; 3: 520-21.
21. O’Fallon WM, Labarthe DR, Kurland LT. Rauwolfia derivatives and breast cancer: a case-control study in Olmstead county, Minnesota. Lancet 1975; 2: 292-6.
22. Wallace RB, Sherman BM, Bean JA, et al. Thyroid hormone use in patients with breast cancer: absence of an association. JAMA 1978; 239: 958.
23. Armstrong B, Jick H. Thyroid supplements and breast cancer (letter). JAMA 1976; 236: 2744.